Orion Corporation Invites Analysts to Capital Markets Day
Orion Corporation is excited to announce its forthcoming Capital Markets Day, a key event designed for analysts, institutional investors, bankers, and media representatives. This engaging event is scheduled to take place in the afternoon in Helsinki, providing a platform for in-depth exploration of Orion's vision and strategic direction.
What to Expect During the Event
During this Capital Markets Day, attendees will have the opportunity to hear from Orion's President and CEO, Liisa Hurme, along with CFO René Lindell and other dynamic members of the Executive Management Board. They will share valuable insights into the company’s growth strategy, financial objectives, and the various business segments Orion is involved in.
Networking Opportunities and Q&A Session
The event will also encourage interactive engagement, allowing participants to pose questions to the speakers. This presents a unique chance to gain clarity and deeper understanding of Orion's plans and operations moving forward. Interactions during discussions often lead to valuable insights, so attendees are encouraged to take advantage of this opportunity.
Event Logistics and Participation Details
Orion's Capital Markets Day will be held at the event studio Eliel, located at Sanomatalo in Helsinki. Additionally, for those who prefer to join remotely, there will be a webcast option available. Detailed information, including the webcast link and presentation materials, will be accessible on Orion’s investor website in due time.
Save the Date
A formal invitation detailing the agenda and registration procedures will be issued as the event date approaches. Interested participants are encouraged to mark their calendars for this significant event, which promises to shed light on Orion's future endeavors.
Orion Corporation: A Brief Overview
With a rich history of over a century, Orion Corporation has established itself as a prominent player in the global pharmaceutical industry. The company is dedicated to enhancing well-being through the development, manufacturing, and marketing of both human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients.
Commitment to Innovative Health Solutions
Orion is recognized for its extensive portfolio, comprising a mix of proprietary and generic medicines, as well as consumer health products. Their focused R&D initiatives primarily revolve around oncology and pain management, with proprietary treatments developed to address challenges in cancer care, neurological disorders, and respiratory diseases.
Current Market Performance
In 2023, Orion's net sales were reported at an impressive EUR 1,190 million, reflecting the company’s strength and market position. By the end of the year, Orion employed around 3,600 professionals, showcasing its commitment to growth and development within the industry. Orion's A and B shares are traded on Nasdaq Helsinki, continuing to attract attention from investors globally.
Frequently Asked Questions
What is the purpose of Orion's Capital Markets Day?
The Capital Markets Day offers insights into Orion's growth strategy, financial objectives, and opportunities for engagement with executives.
When will the event take place?
The event is scheduled for an afternoon gathering in Helsinki, with a date to be communicated through a formal invitation.
Who will speak at the event?
Keynote speakers will include Liisa Hurme, CEO, and CFO René Lindell, along with other members of the Executive Management Board.
Is remote participation available?
Yes, a webcast option will be provided for those who cannot attend in person.
How can I find more information about Orion Corporation?
For more information, visit Orion’s investor website or reach out to their Investor Relations contacts.
